Microcap Ledger NextCure, Inc. $NXTC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Baltimore, MD
- Fiscal year end
- December 31
- Shares outstanding
- 4,577,359 [10-Q 2026-08-06]
What the company doesAI summary of filing
NextCure, Inc. is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) to treat cancer patients resistant to current therapies. The company's lead candidates are SIM0505, a CDH6-targeted ADC licensed from Zaiming Pharmaceuticals that is in Phase 1 clinical trials for solid tumors including ovarian and endometrial cancers, and LNCB74, a B7-H4-targeted ADC being co-developed with LigaChem Biosciences that is also in Phase 1 trials for breast, ovarian, and endometrial cancers. NextCure has no approved products or product revenues and does not expect to achieve profitability in the foreseeable future; the company is pre-revenue and will require substantial additional financing to continue operations. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$24.69M | −$23.08M | $15.26M | [S-4/A 2026-10-01] |
| FY ended Dec 2025 | — | −$55.84M | −$49.61M | $25.98M | [S-4/A 2026-10-01] |
| FY ended Dec 2024 | — | −$55.65M | −$40.80M | $27.73M | [S-4/A 2026-10-01] |
- Quarterly cash burn
- −$11.54M
- Cash runway Estimate
- ~4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 28,006,684 | [10-Q 2024-11-07] |
| 2025-03-03 | 28,006,684 | [10-K 2025-03-06] |
| 2025-04-28 | 28,050,191 | [10-Q 2025-05-01] |
| 2025-08-04 | 2,676,110 | [10-Q 2025-08-07] |
| 2025-10-31 | 2,679,822 | [10-Q 2025-11-05] |
| 2026-02-27 | 3,560,410 | [10-K 2026-03-05] |
| 2026-05-01 | 3,612,096 | [10-Q 2026-05-07] |
| 2026-07-31 | 4,577,359 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-11-26; declared effective 2025-12-11 [S-3 2025-11-26]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-02-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-02-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-10 | Simcere Zaiming, Inc. | sell | 30,000 | $6.16 | [4 2026-08-12] |
| 2026-07-31 | Adar1 Capital Management, Llc | buy | 3,300 | $4.98 | [4 2026-08-03] |
| 2026-07-31 | Adar1 Capital Management, Llc | buy | 25,000 | $4.98 | [4 2026-08-03] |
| 2026-07-31 | Adar1 Capital Management, Llc | buy | 8,003 | $4.80 | [4 2026-08-03] |
| 2026-07-30 | Adar1 Capital Management, Llc | buy | 50,000 | $4.97 | [4 2026-08-03] |
| 2026-07-30 | Adar1 Capital Management, Llc | buy | 20,000 | $5.00 | [4 2026-08-03] |
| 2026-07-30 | Adar1 Capital Management, Llc | buy | 20,000 | $5.00 | [4 2026-08-03] |
| 2026-07-30 | Adar1 Capital Management, Llc | buy | 25,000 | $4.81 | [4 2026-08-03] |
| 2026-07-30 | Adar1 Capital Management, Llc | buy | 100,000 | $4.90 | [4 2026-08-03] |
| 2026-07-30 | Adar1 Capital Management, Llc | buy | 77,850 | $4.96 | [4 2026-08-03] |
| 2026-07-29 | Adar1 Capital Management, Llc | buy | 1,810 | $5.00 | [4 2026-07-29] |
| 2026-07-29 | Adar1 Capital Management, Llc | buy | 1,600 | $5.00 | [4 2026-07-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-25 | 8-K | Other events |
| 2026-09-03 | 8-K | Material agreement entered |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-14 | 8-K | Material agreement entered; Exit or disposal costs; Change in control |
| 2026-06-25 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-01 | 8-K | Regulation FD disclosure; Other events |
Alerts for $NXTC
Email me when NextCure, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.